Jun Wang1, Shi-Ping Yang2, Ping Zhou1, Chen-Lu Lian1, Jian Lei3, Li Hua3, Zhen-Yu He4, San-Gang Wu1. 1. Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China. 2. Department of Radiation Oncology, Hainan General Hospital (Hainan Affiliated Hospital of Medical University), Haikou, Hainan, People's Republic of China. 3. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China. 4. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China.
Abstract
BACKGROUND: We aim to assess the value of locoregional treatment (LRT) including breast-conserving surgery (BCS), mastectomy (MAST), and radiotherapy (RT) in patients with de novo stage IV breast cancer. METHODS: Patients with de novo stage IV breast cancer were retrospectively identified from the Surveillance, Epidemiology, and End Results database between 2004 and 2014. Kaplan-Meier analysis, log-rank tests, propensity score matching (PSM), and the multivariate Cox proportional model were used for statistical analysis. RESULTS: A total of 5798 patients were identified including 849 (14.6%), 763 (13.2%), 2338 (40.3%), and 1848 (31.9%) who received BCS alone, BCS+RT, MAST alone, and MAST+RT, respectively. The proportions of receiving BCS decreased from 35.9% in 2004 to 26.2% in 2014 (p = 0.002), and the probability of patients receiving MAST increased from 64.1% in 2004 to 74.8% in 2014 (p = 0.002). Before PSM, there was a significant difference in breast cancer-specific survival (BCSS) among the treatment arms. Patients who received RT had better BCSS, the 5-year BCSS was 40.5%, 52.3%, 41.5%, and 47.7% in patients treated with BCS alone, BCS+RT, MAST alone, and MAST+RT, respectively (p < 0.001). In the PSM cohort, patients treated with BCS alone had lower 5-year BCSS compared to those treated with BCS+RT (43.9% and 52.1%, p = 0.002). However, there were comparable 5-year BCSS between BCS+RT and MAST alone groups (51.3% and 50.1%, p = 0.872), and BCS+RT and MAST+RT cohorts (51.5% and 55.7%, p = 0.333). Similar results were confirmed in multivariate analysis. CONCLUSIONS: Postoperative RT improves BCSS in patients with de novo stage IV breast cancer, and BCS+RT shows a non-inferior outcome compared to MAST+RT. BCS+RT may be the optimal local management of de novo stage IV breast cancer.
BACKGROUND: We aim to assess the value of locoregional treatment (LRT) including breast-conserving surgery (BCS), mastectomy (MAST), and radiotherapy (RT) in patients with de novo stage IV breast cancer. METHODS:Patients with de novo stage IV breast cancer were retrospectively identified from the Surveillance, Epidemiology, and End Results database between 2004 and 2014. Kaplan-Meier analysis, log-rank tests, propensity score matching (PSM), and the multivariate Cox proportional model were used for statistical analysis. RESULTS: A total of 5798 patients were identified including 849 (14.6%), 763 (13.2%), 2338 (40.3%), and 1848 (31.9%) who received BCS alone, BCS+RT, MAST alone, and MAST+RT, respectively. The proportions of receiving BCS decreased from 35.9% in 2004 to 26.2% in 2014 (p = 0.002), and the probability of patients receiving MAST increased from 64.1% in 2004 to 74.8% in 2014 (p = 0.002). Before PSM, there was a significant difference in breast cancer-specific survival (BCSS) among the treatment arms. Patients who received RT had better BCSS, the 5-year BCSS was 40.5%, 52.3%, 41.5%, and 47.7% in patients treated with BCS alone, BCS+RT, MAST alone, and MAST+RT, respectively (p < 0.001). In the PSM cohort, patients treated with BCS alone had lower 5-year BCSS compared to those treated with BCS+RT (43.9% and 52.1%, p = 0.002). However, there were comparable 5-year BCSS between BCS+RT and MAST alone groups (51.3% and 50.1%, p = 0.872), and BCS+RT and MAST+RT cohorts (51.5% and 55.7%, p = 0.333). Similar results were confirmed in multivariate analysis. CONCLUSIONS: Postoperative RT improves BCSS in patients with de novo stage IV breast cancer, and BCS+RT shows a non-inferior outcome compared to MAST+RT. BCS+RT may be the optimal local management of de novo stage IV breast cancer.
Authors: J Ruiterkamp; M F Ernst; L V van de Poll-Franse; K Bosscha; V C G Tjan-Heijnen; A C Voogd Journal: Eur J Surg Oncol Date: 2009-04-26 Impact factor: 4.424
Authors: Elżbieta Cipora; Magdalena Konieczny; Irena Dorota Karwat; Wojciech Roczniak; Magdalena Babuśka-Roczniak Journal: Ann Agric Environ Med Date: 2018-06-11 Impact factor: 1.447
Authors: M Untch; D Augustin; J Ettl; R Haidinger; N Harbeck; H-J Lück; D Lüftner; F Marmé; L Müller; F Overkamp; E Ruckhäberle; M Thill; C Thomssen; R Wuerstlein; N Marschner Journal: Geburtshilfe Frauenheilkd Date: 2016-02 Impact factor: 2.915
Authors: David H A Nguyen; Pauline T Truong; Cheryl Alexander; Caroline V Walter; Emily Hayashi; Jennifer Christie; Mary Lesperance Journal: Int J Radiat Oncol Biol Phys Date: 2012-02-11 Impact factor: 7.038
Authors: Stephen K Chia; Caroline H Speers; Yulia D'yachkova; Anna Kang; Suzanne Malfair-Taylor; Jeff Barnett; Andy Coldman; Karen A Gelmon; Susan E O'reilly; Ivo A Olivotto Journal: Cancer Date: 2007-09-01 Impact factor: 6.860
Authors: Michael Retsky; Romano Demicheli; William J M Hrushesky; Patrice Forget; Marc De Kock; Isaac Gukas; Rick A Rogers; Michael Baum; Vikas Sukhatme; Jayant S Vaidya Journal: Curr Med Chem Date: 2013 Impact factor: 4.530
Authors: Anne-Michelle Noone; Jennifer L Lund; Angela Mariotto; Kathleen Cronin; Timothy McNeel; Dennis Deapen; Joan L Warren Journal: Med Care Date: 2016-09 Impact factor: 3.178